

GLAXOSMITHKLINE PLC  
Form 6-K  
October 21, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 21 October 2016

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Dr M M Slaoui
  - b) Position/status Chairman, Global Vaccines
  - c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument American Depositary Shares ('ADSs')  
ISIN: US37733W1053
  - b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to shareholders on 13 October 2016.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
\$41.4815	10.943

 Aggregated information n/a (single transaction)
  - d) Aggregated volume Price
  - e) Date of the transaction 2016-10-20
  - f) Place of the transaction NYSE (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr D E Troy
  - b) Position/status SVP & General Counsel
  - c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument American Depositary Shares ('ADSs')  
ISIN: US37733W1053

	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 13 October 2016.
b) Nature of the transaction	
c) Price(s) and volume(s)	Price(s)      Volume(s) \$41.4815      1,196.207
Aggregated information	n/a (single transaction)
d) Aggregated volume Price	
e) Date of the transaction	2016-10-20
f) Place of the transaction	New York Stock Exchange (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Dr K Slaoui
b) Position/status	PCA of Dr M M Slaoui (Chairman, Global Vaccines)
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
--	---

	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 13 October 2016.
b) Nature of the transaction	
c) Price(s) and volume(s)	Price(s)      Volume(s) \$41.4815      26.393
Aggregated information	n/a (single transaction)
d) Aggregated volume Price	
e) Date of the transaction	2016-10-20
f) Place of the transaction	NYSE (XNYS)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)  
Date: October 21, 2016

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc